Current Wegovy labeling reports constipation among common adverse reactions, with 24% of adults receiving Wegovy 2.4 mg injection reporting it in the weight-reduction trials summarized in the label
Major medical sources note very limited research on lipotropic injections for weight loss, and that any weight change is often more attributable to the overall program (nutrition, activity, calorie intake) than the injection alone
Using the wrong solvent Some peptides require specific solvents
The revised Cochrane risk-of-bias tool for randomised trials (RoB 2) was used to appraise evidence
Applications ELISA, WB, IF, Flow Cytometry Dilutions ELISA: 1:128,000, WB: 0.1-1g/ml, IF: 10g/ml, Flow Cytometry: 10g/ml Reactivity Human, Rat, Porcine Immunogen Synthetic peptide corresponding to the internal region of human GLP-1R